A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
-
REGULATORY PM Advisors Make Irregular Call for Properly Rewarding Innovation to Boost Japan’s Drug Discovery Capabilities
May 29, 2023
-
REGULATORY Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
-
BUSINESS Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
-
ORGANIZATION New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
-
ORGANIZATION Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
-
REGULATORY Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
May 26, 2023
-
BUSINESS Some 400 General Employees Likely Leaving Bayer under Redundancy Program
May 25, 2023
-
BUSINESS Lilly’s Omvoh Launch Set for June 21; BioMarin’s Palynziq Now Available
May 25, 2023
-
BUSINESS Novartis Japan Rolling Out New Operational Model Tailored to Local Needs: President
May 24, 2023
-
COMMENTARY Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
-
REGULATORY LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
-
REGULATORY Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
May 23, 2023
-
REGULATORY MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
May 23, 2023
-
BUSINESS Sawai and Towa Profits Tank 50% on Flat Sales in Japan: FY2022 Earnings
May 22, 2023
-
BUSINESS Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
May 22, 2023
-
ORGANIZATION Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
-
BUSINESS Qol to Further Expand Espha's AG Biz, Eyes Biosame Territory: Exec
May 19, 2023
-
BUSINESS Lecanemab’s Social Value in Japan Simulated at 4.7 Million Yen per Patient/Year: Eisai
May 18, 2023
-
REGULATORY Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
May 18, 2023
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…